BioArctic

BioArctic Pre-Tax Margin

The Pre-Tax Profit Margin of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 62.81 %. In the previous year, Pre-Tax Profit Margin was -73.64 % — a change of -185.29% (higher).

Pre-Tax Margin

62.81 %

YoY

-185.29%

Last updated:

Pre-Tax Profit Margin of BioArctic is 2025 62.81 % . Pre-Tax Profit Margin of BioArctic was 2024 -73.64 % . It decreases by -185.29% higher compared to the previous year.

The BioArctic Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
68.57 SEK
Jan 1, 2019
40.09 SEK
Jan 1, 2020
-139.05 SEK
Jan 1, 2021
-607.07 SEK
Jan 1, 2022
-4.89 SEK
Jan 1, 2023
44.88 SEK
Jan 1, 2024
-73.64 SEK
Jan 1, 2025
62.81 SEK
The BioArctic Pre-Tax Margin history
YEARPre-Tax MarginYoY
62.81 %-185.29%
-73.64 %-264.07%
44.88 %-1,017.59%
-4.89 %-99.19%
-607.07 %+336.60%
-139.05 %-446.79%
40.09 %-41.53%
68.57 %+390.03%
13.99 %-80.06%
70.20 %+509.11%
11.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Pre-Tax Profit Margin of BioArctic is 62.81 % in 2025.

Pre-Tax Profit Margin of BioArctic changed from -73.64 % to 62.81 %, representing a -185.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin BioArctic since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BioArctic

All Key Metrics — BioArctic